Chronic, recurrent Lymphocytic Leukemia Active Not Recruiting Phase 2 Trials for Ibrutinib (DB09053)

Also known as: Recurrent Chronic Lymphocytic Leukemia

IndicationStatusPhase
DBCOND0112002 (Chronic, recurrent Lymphocytic Leukemia)Active Not Recruiting2
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT02869633Ibrutinib in Treating Patients With Refractory or Relapsed Lymphoma After Donor Stem Cell TransplantTreatment
NCT02756897Venetoclax and Ibrutinib in Treating Patients With Chronic or Small Lymphocytic LeukemiaTreatment
NCT03045328Venetoclax and Ibrutinib in Patients With Relapsed/Refractory CLL or SLLTreatment
NCT02420912Nivolumab and Ibrutinib in Treating Patients With Relapsed, Refractory, or High-Risk Untreated Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, or Richter TransformationTreatment